Heart failure in cardiorenal syndromes
- 作者: Kharchenko EP1
-
隶属关系:
- 期: 卷 85, 编号 1 (2013)
- 页面: 85-91
- 栏目: Editorial
- ##submission.dateSubmitted##: 10.04.2020
- ##submission.datePublished##: 15.01.2013
- URL: https://ter-arkhiv.ru/0040-3660/article/view/31218
- ID: 31218
如何引用文章
全文:
详细
This review considers the classification of cardiorenal syndromes (CRS), the pathogenesis of heart failure, and a search for therapeutic targets for its treatment, biomarkers for heart and kidney failure, difficulties in therapy and reversion of the pathogenetic continuum of CRS, and promises for the use of some new technologies to treat this condition.
全文:
Сердечная недостаточность при кардиоренальных синдромах. - Аннотация. В лекции рассматриваются классификация кардиоренальных синдромов (КРС), проблемы патогенеза сердечной недостаточности и поиска терапевтических мишеней для ее лечения, биомаркеры сердечной и почечной недостаточности, трудности терапии и реверсии патогенетического континуума КРС, а также перспективы применения некоторых новых технологий для лечения КРС.×
参考
- IwanagaY., Miyazaki S. Heart failure, chronic kidney disease, and biomarkers. Circ J 2010; 74: 1274-1282.
- Goh C.Y., Ronco C. Cardio-renal syndromes. Journal of Renal Care 2010; 36 (Suppl. 1): 9-17.
- Edelman G.М., Gaily J.A. Degeneracy and complexity in biological systems. Proc Natl Acad Sci USA 2001; 98: 13 763-13 768.
- Kong S.W., Bodyak N., Yue P. et al. Genetic expression profiles during physiological and pathological cardiac hypertrophy and heart failure in rats.. Physiol Genomics 2005; 21: 34-42.
- SharmaU.C., Pokharel S., Evelo С. et al. A systematic review of large scale and heterogeneous gene array data in heart failure. J Mol Cel Cardiol 2005; 38: 425-432.
- Амбурже Ж., Рише Г., Кроение Ж., Функ-Брентано Ж.Л. Почечная недостаточность. М: Медицина 1965: 403.
- Mann D. Mechanisms and models in heart failure. Circulation 1999; 100: 999-1008.
- Mann D. (ed). Heart failure. Saunders 2004.
- Bongartz L.G., Cramer M.J., Doevendans P.A. et al. The severe cardiorenal syndrome: "Guyton revisited". Eur Heart J 2005; 26: 11-17.
- Shah B.N., Greaves K. The Cardiorenal Syndrome. Intern J Nephrol 2011; ID 920195.
- Ingwall J.S. Energetic basis for heart failure. In: D. Mann (ed). Heart failure. Saunders 2004: 91-108.
- Giordano F.J. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 2005; 115: 500 -508.
- Mann D. Inflammatory mediators and the failing heart. Circ Res 2002; 91: 988-998.
- Gehi A.K., Pinney S.P., Gass A. Recent diagnostic and therapeutic innovations in heart failure management. Mount Sinai J Med 2005; 72:176-184.
- Watts Т.Н. TNF/TNFR family members in costymlation of T cell responses. Ann Rev Immunol 2005; 23: 23-68.
- Myers R.R., Campana W.M., Shubayev V.I. The role of neuroinflammation in neuropathic pain: mechanisms and therapeutic targets. Drug Discovery Today 2006; 11: 8-20.
- Cruz D.N., Goh С.Y., Haase-Fielitz A. et al. Early biomarkers of renal injury. Congest Heart Fail 2010; 16 (4): S25-S31.
- Tesch G.H. Serum and urine biomarkers of kidney disease: a pathophysiological perspective. Nephrology 2010; 15: 609-616.
- Хакен Г. Синергетика. M: Мир 1985: 419.
- Longhini С., Molino С., Fabbian F. Cardiorenal syndrome: still not a defined entity. Clin Exp Nephrol 2010; 14: 12-21.
- House A.A., Haapio М., Lassus J. et al. Therapeutic strategies for heart failure in cardiorenal syndromes. Am J Kidney Dis 2010; 56: 759-773.
- Liu P.P. Cardiorenal syndrome in heart failure: a cardiologist's perspective. Can J Cardiol 2008; 24 (Suppl B): 25B-29B.
- Merhaut S., Trupp R.J. Cardiorenal dysfunction. AACN Advanced Critical Care 2010; 21: 357-364.
- Kociol R., Rogers J., Shaw A. Organ cross talk in the critically ill: the heart and kidney. Blood Purif 2009; 27: 311-320.
- Sarraf М., Masoumi A., Schrier R.W. Cardiorenal syndrome in acute decompensated heart failure. Clin J Am Soc Nephrol 2009; 4: 2013-2026.
- Viswanathan G., Gilbert S. The cardiorenal syndrome: making the connection. Intern J Nephrol 2011; ID 283137.
- Mahapatra H.S., Lalmalsawma R., Singh N.P. et al. Cardiorenal syndrome. Iranian J Kidney 2009; 3: 61-70.
- Ronco C., Maisel A. Volume overload and cardiorenal syndromes. Congest Heart Fail 2010; 16 (4): Si-Siv.
- Kazory A., Ross E.A. Emerging therapies for heart failure: renal mechanisms and effects. Heart Fail Rev 2010; doi: 10.1007/sl0741-010-9191-5.
- Felker G.M. Diuretic management in heart failure. Congest Heart Fail 2010; 16 (4): S68-S72.
- Thompson K.A., Philip K.J., Barbagelata A., Schwarz E.R. The new concept of interventional heart failure therapy - part 1: electrical therapy, treatment of CAD, fluid removal, and ventricular support. J Cardiovasc Pharmacol Ther 2010; 15 (2): 102-111.
- Thompson K.A., Philip K.J., Simsir S., Schwarz E.R. The new concept of "interventional heart failure therapy": part 2 - inotropes, valvular disease, pumps, and transplantation. J Cardiovasc Pharmacol Ther 2010; 15 (3): 231-243.
- Thom R. Catastrophe theory: its present state and future perspectives. Warwick: Springer Verlag 1974; 75.
- Пригожин И.P., Стенгерс И. Порядок из хаоса. М: Прогресс 1986: 432.
- Tang Z., McGowan В.S., Huber S.А. et al. Gene expression profiling during the transitic to failure in TNF-alpha over-expressing mice demonstrates the development of autoimmune myocarditis. Mol Cell Cardiol 2004; 36: 515-530.
- Margulies K.B., Bednarik D.P., Dries L. Genomics, Transcriptional Profiling, and Heart Failure. J Am Coll Cardiol 2009; 53: 1752-1759.
- Liu Ning, Olson E.N. MicroRNA regulatory networks in cardiovascular development. Developmental Cell 2010; 18: 510-515.
- McLeod H.L. Using patient DNA to optimize therapy in heart failure patients: a move toward perfection. Heart Fail Rev 2010; 15: 183-185.
- Харченко Е.П. Сердечная недостаточность: патогенетический континуум и биомаркеры. Кардиология 2012; 3: 53-64.
补充文件
![](/img/style/loading.gif)